Summary

KEY FINDINGS
The Asia-Pacific retinal imaging devices market size is valued at $982.75 million as of 2026 and is expected to reach $1,991.68 million by 2034, progressing with a CAGR of 9.23% during the forecast years, 2026-2034.

MARKET INSIGHTS
Asia-Pacific emerges as the fastest-growing region for retinal imaging devices, driven by massive diabetic populations, rapid economic development, and expanding healthcare infrastructure across emerging markets. The region harbors the world's largest diabetes burden, with China alone accounting for approximately 141 million diabetic individuals according to recent estimates. Moreover, rising middle-class populations increasingly demand access to advanced ophthalmology services, creating substantial opportunities for retinal diagnostic imaging equipment.
According to research published in Nature Communications, diabetic retinopathy prevalence in China reaches 16.3% among adults with diabetes, with vision-threatening retinopathy affecting 3.2% of this population. Additionally, geographic variations reveal significantly higher prevalence rates in northern regions compared to southern areas, highlighting diverse market dynamics across the continent. Governments throughout the Asia-Pacific prioritize healthcare modernization, allocating substantial budgets toward medical technology procurement and hospital infrastructure development.
Furthermore, regional manufacturers from Japan, South Korea, and India compete alongside established Western companies, offering cost-effective alternatives suited to local market conditions. The aging demographic across developed Asian economies like Japan, South Korea, and Singapore further amplifies demand for retinal imaging equipment to address age-related macular degeneration and glaucoma.

REGIONAL ANALYSIS
The Asia-Pacific retinal imaging devices market growth assessment includes the analysis of China, Japan, India, South Korea, Indonesia, Vietnam, Thailand, Australia & New Zealand, and Rest of Asia-Pacific.
China dominates the Asia-Pacific retinal imaging devices market due to its enormous diabetic population, aggressive healthcare infrastructure expansion, and government emphasis on chronic disease management. The nation faces unprecedented challenges in managing diabetic eye disease among 141 million diabetic individuals, creating a massive demand for retinal screening technologies. National prevalence surveys reveal diabetic retinopathy affects 16.3% of Chinese adults with diabetes, with rates significantly elevated in northern provinces compared to southern regions.
Urban-rural disparities present both challenges and opportunities, as studies indicate rural areas experience 34.0% diabetic retinopathy prevalence compared to 18.7% in urban settings. This geographic imbalance drives government initiatives to deploy portable retinal imaging devices through mobile screening programs reaching underserved populations. Moreover, China's Healthy China 2030 initiative prioritizes chronic disease prevention, mandating systematic diabetic retinopathy screening programs across primary healthcare facilities.
Despite lacking a unified national screening program, pilot teleophthalmology projects demonstrate significant potential for expanding retinal diagnostic access. Provincial governments invest heavily in digital health infrastructure, creating opportunities for vendors offering cloud-connected fundus cameras compatible with remote grading platforms.
Additionally, China's domestic medical device industry produces cost-competitive retinal imaging equipment, though high-end optical coherence tomography systems remain dominated by Western manufacturers. The country's growing middle class increasingly seeks premium eye care services at private ophthalmology chains, supporting the adoption of advanced retinal diagnostic technologies. Furthermore, regulatory reforms streamline medical device approvals, accelerating market entry for innovative retinal imaging solutions.
Consequently, manufacturers offering diverse product portfolios spanning entry-level fundus cameras for township hospitals to sophisticated OCT systems for tertiary facilities capture substantial market share. Chinese healthcare authorities also promote artificial intelligence integration for automated diabetic retinopathy screening, positioning the nation as a major growth engine for AI-powered retinal diagnostic equipment throughout the forecast period.
Japan exhibits mature demand for retinal imaging devices, characterized by universal health insurance coverage, advanced medical technology adoption, and emphasis on preventive healthcare. The nation's aging society faces elevated risks of diabetic retinopathy and age-related macular degeneration, necessitating a comprehensive retinal screening infrastructure.
Research from the Japan Diabetes Complications Study documented diabetic retinopathy incidence rates of 38.3 per 1,000 person-years among type 2 diabetes patients, with higher HbA1c levels, longer diabetes duration, and elevated blood pressure significantly associated with disease development. Japanese ophthalmology practices extensively utilize high-specification optical coherence tomography systems for detailed retinal analysis, reflecting a strong preference for premium diagnostic equipment.
Moreover, the country's medical device regulatory framework emphasizes rigorous safety and efficacy standards, creating barriers to entry but ensuring high-quality product availability. Japan's ophthalmologists demonstrate strong loyalty to established brands like Topcon Corporation, Nidek Co Ltd, and Carl Zeiss Meditec, which maintain extensive support networks throughout the archipelago.
The universal health insurance system provides comprehensive coverage for diagnostic ophthalmology procedures, removing financial barriers to retinal imaging access. Consequently, replacement cycles for existing equipment drive steady market growth as facilities upgrade to the latest-generation OCT-angiography systems and ultra-widefield imaging platforms incorporating artificial intelligence analysis capabilities.

SEGMENTATION ANALYSIS
The Asia-Pacific retinal imaging devices market is segmented into device, application, and indication. The indication segment is further categorized into diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, retinal vein occlusion, and other indications.
Diabetic retinopathy dominates the indication segment across Asia-Pacific markets due to the region's massive diabetes epidemic and associated sight-threatening complications. Approximately one-third of the global diabetic population resides in the Asia-Pacific, creating unprecedented demand for systematic retinal screening programs.
Healthcare providers throughout the region deploy fundus cameras and optical coherence tomography systems specifically for detecting diabetic macular edema, proliferative changes, and other vision-threatening manifestations. National diabetes associations advocate for annual retinal examinations, driving consistent utilization of ophthalmic diagnostic equipment across primary care facilities, diabetes clinics, and specialty ophthalmology centers.
Moreover, diabetic retinopathy represents a preventable cause of blindness when detected early through systematic screening, motivating government health ministries to invest in retinal imaging infrastructure. Countries like Thailand, Singapore, and Malaysia implement organized diabetic eye screening programs modeled after successful Western initiatives, requiring standardized retinal photography equipment for all participating facilities.
Additionally, diabetic retinopathy screening generates recurring revenue streams for ophthalmology practices and diagnostic centers, as diabetic patients require lifelong monitoring at recommended intervals. The segment benefits from expanding health insurance coverage throughout middle-income Asian countries, which increasingly reimburse diabetic retinopathy screening examinations.
Furthermore, artificial intelligence algorithms specifically trained for diabetic retinopathy detection achieve regulatory approvals throughout Asia-Pacific, accelerating automated screening adoption in primary care settings. Consequently, vendors emphasizing diabetic retinopathy applications in their marketing strategies and product development roadmaps capture disproportionate market share throughout the region's diverse healthcare landscapes.

COMPETITIVE INSIGHTS
Some of the top players operating in the Asia-Pacific retinal imaging devices market include Topcon Corporation, Nidek Co Ltd, Canon Inc, Forus Health Pvt Ltd, etc.
Topcon Corporation stands as a leading Japanese manufacturer of ophthalmic diagnostic equipment, headquartered in Tokyo with extensive global operations throughout Asia-Pacific and beyond. The company specializes in comprehensive retinal imaging solutions, particularly its acclaimed 3D OCT series, combining spectral-domain optical coherence tomography with integrated fundus photography.
Topcon's product portfolio encompasses advanced diagnostic platforms, including swept-source OCT devices with deep range imaging capabilities, non-mydriatic fundus cameras, widefield retinal imaging systems, and multimodal imaging workstations for comprehensive eye examinations.
Additionally, the company offers the SIGNAL handheld retinal camera designed for mobile screening programs and point-of-care applications in rural settings. Topcon serves diverse customer segments throughout Asia-Pacific, including university hospitals, retina specialty practices, comprehensive ophthalmology clinics, optometry offices, and government screening programs. The company's business model emphasizes strong regional partnerships, comprehensive after-sales support networks, extensive training programs for clinical staff, and continuous technology innovation responding to evolving clinical needs throughout rapidly developing Asian healthcare markets.

COMPANY PROFILES
1. CANON INC
2. CARL ZEISS MEDITEC AG
3. ESCALON MEDICAL CORP
4. FORUS HEALTH PVT LTD
5. HEIDELBERG ENGINEERING GMBH
6. KOWA COMPANY LTD
7. NIDEK CO LTD
8. OPTOS PLC
9. SANTEC CORPORATION
10. TOPCON CORPORATION

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & FORECAST
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. WIDESPREAD ADOPTION OF FUNDUS CAMERAS AND OCT SYSTEMS IS DRIVEN BY RISING SCREENING NEEDS FOR DIABETIC RETINOPATHY AND AGE-RELATED MACULAR DEGENERATION
2.5.2. HOSPITALS AND DIAGNOSTIC CLINICS ACCOUNT FOR THE LARGEST SHARE DUE TO HIGH PATIENT FOOTFALL AND INTEGRATED OPHTHALMOLOGY SETUPS
2.5.3. PORTABLE AND HANDHELD RETINAL IMAGING DEVICES ARE GAINING TRACTION IN RURAL AND PRIMARY CARE SETTINGS
2.5.4. DEVELOPED MARKETS DOMINATE REVENUE, WHILE EMERGING ECONOMIES SHOW FASTER VOLUME GROWTH
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING GLOBAL PREVALENCE OF DIABETES AND AGING POPULATION IS EXPANDING THE AT-RISK PATIENT BASE
3.1.2. GOVERNMENT AND NGO LED EYE SCREENING PROGRAMS ARE BOOSTING DEMAND FOR RETINAL DIAGNOSTIC TOOLS
3.1.3. TECHNOLOGICAL ADVANCES IN OCT AI ASSISTED DIAGNOSTICS AND IMAGE QUALITY ARE IMPROVING CLINICAL OUTCOMES
3.1.4. RISING AWARENESS AMONG PHYSICIANS AND PATIENTS ABOUT EARLY DETECTION OF RETINAL DISORDERS IS SUPPORTING MARKET EXPANSION
3.2. KEY RESTRAINTS
3.2.1. HIGH CAPITAL COST OF ADVANCED RETINAL IMAGING SYSTEMS LIMITS ADOPTION IN SMALL CLINICS
3.2.2. LACK OF TRAINED OPHTHALMOLOGISTS AND TECHNICIANS CONSTRAINS EFFECTIVE UTILIZATION IN LOW-INCOME REGIONS
3.2.3. REIMBURSEMENT VARIABILITY ACROSS COUNTRIES AFFECTS PURCHASE DECISIONS BY HEALTHCARE PROVIDERS
3.2.4. REGULATORY APPROVAL AND DEVICE CERTIFICATION REQUIREMENTS CAN DELAY PRODUCT COMMERCIALIZATION
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. INTEGRATION OF ARTIFICIAL INTELLIGENCE FOR AUTOMATED RETINAL IMAGE ANALYSIS IS ACCELERATING
4.1.2. SHIFT TOWARD NON-MYDRIATIC AND PATIENT-FRIENDLY IMAGING SYSTEMS IS IMPROVING SCREENING COMPLIANCE
4.1.3. GROWING USE OF TELE OPHTHALMOLOGY IS DRIVING DEMAND FOR CONNECTED RETINAL IMAGING DEVICES
4.1.4. MANUFACTURERS ARE FOCUSING ON COMPACT AND PORTABLE DESIGNS TO EXPAND POINT OF CARE APPLICATIONS
4.2. PORTER’S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. RAW MATERIAL SUPPLIERS
4.6.2. OPTICAL COMPONENTS
4.6.3. DEVICE MANUFACTURING
4.6.4. SOFTWARE DEVELOPMENT
4.6.5. DISTRIBUTION CHANNELS
4.6.6. HOSPITALS AND CLINICS
4.6.7. AFTERSALES SUPPORT
4.7. KEY BUYING CRITERIA
4.7.1. IMAGE RESOLUTION
4.7.2. CLINICAL ACCURACY
4.7.3. EASE OF USE
4.7.4. TOTAL COST OWNERSHIP
4.8. REGULATORY FRAMEWORK
5. RETINAL IMAGING DEVICES MARKET BY DEVICE
5.1. OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES
5.1.1. SPECTRAL-DOMAIN OCT (SD-OCT)
5.1.2. SWEPT-SOURCE OCT (SS-OCT)
5.1.3. HANDHELD OCT
5.2. FLUORESCEIN ANGIOGRAPHY DEVICES
5.3. FUNDUS CAMERAS
5.3.1. MYDRIATIC FUNDUS CAMERAS
5.3.2. NON-MYDRIATIC FUNDUS CAMERAS
5.3.3. HYBRID FUNDUS CAMERAS
5.3.4. ROP FUNDUS CAMERAS
5.4. RETINAL ULTRASOUND IMAGING SYSTEMS
5.4.1. OPHTHALMIC A-SCAN ULTRASOUND
5.4.2. OPHTHALMIC B-SCAN ULTRASOUND
5.4.3. OPHTHALMIC ULTRASOUND BIOMICROSCOPES
5.4.4. OPHTHALMIC PACHYMETERS
5.5. ULTRA WIDEFIELD RETINAL IMAGING DEVICES
5.6. WIDEFIELD RETINAL IMAGING DEVICES
5.7. OTHER DEVICES
6. RETINAL IMAGING DEVICES MARKET BY APPLICATION
6.1. DISEASE DIAGNOSIS
6.2. TREATMENT MONITORING
6.3. RESEARCH AND DEVELOPMENT
7. RETINAL IMAGING DEVICES MARKET BY INDICATION
7.1. DIABETIC RETINOPATHY
7.2. AGE-RELATED MACULAR DEGENERATION (AMD)
7.3. GLAUCOMA
7.4. RETINAL VEIN OCCLUSION
7.5. OTHER INDICATIONS
8. GEOGRAPHICAL ANALYSIS
8.1. ASIA-PACIFIC
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. ASIA-PACIFIC MARKET DRIVERS
8.1.3. ASIA-PACIFIC RETINAL IMAGING DEVICES MARKET CHALLENGES
8.1.4. KEY PLAYERS IN ASIA-PACIFIC RETINAL IMAGING DEVICES MARKET
8.1.5. COUNTRY ANALYSIS
8.1.5.1. GERMANY
8.1.5.1.1. GERMANY MARKET SIZE & OPPORTUNITIES
8.1.5.2. UNITED KINGDOM
8.1.5.2.1. UNITED KINGDOM MARKET SIZE & OPPORTUNITIES
8.1.5.3. FRANCE
8.1.5.3.1. FRANCE MARKET SIZE & OPPORTUNITIES
8.1.5.4. ITALY
8.1.5.4.1. ITALY MARKET SIZE & OPPORTUNITIES
8.1.5.5. SPAIN
8.1.5.5.1. SPAIN MARKET SIZE & OPPORTUNITIES
8.1.5.6. BELGIUM
8.1.5.6.1. BELGIUM MARKET SIZE & OPPORTUNITIES
8.1.5.7. POLAND
8.1.5.7.1. POLAND MARKET SIZE & OPPORTUNITIES
8.1.5.8. REST OF ASIA-PACIFIC
8.1.5.8.1. REST OF ASIA-PACIFIC MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. CANON INC
9.2.1.1. COMPANY OVERVIEW
9.2.1.2. PRODUCT LIST
9.2.1.3. STRENGTHS & CHALLENGES
9.2.2. CARL ZEISS MEDITEC AG
9.2.2.1. COMPANY OVERVIEW
9.2.2.2. PRODUCT LIST
9.2.2.3. STRENGTHS & CHALLENGES
9.2.3. ESCALON MEDICAL CORP
9.2.3.1. COMPANY OVERVIEW
9.2.3.2. PRODUCT LIST
9.2.3.3. STRENGTHS & CHALLENGES
9.2.4. FORUS HEALTH PVT LTD
9.2.4.1. COMPANY OVERVIEW
9.2.4.2. PRODUCT LIST
9.2.4.3. STRENGTHS & CHALLENGES
9.2.5. HEIDELBERG ENGINEERING GMBH
9.2.5.1. COMPANY OVERVIEW
9.2.5.2. PRODUCT LIST
9.2.5.3. STRENGTHS & CHALLENGES
9.2.6. KOWA COMPANY LTD
9.2.6.1. COMPANY OVERVIEW
9.2.6.2. PRODUCT LIST
9.2.6.3. STRENGTHS & CHALLENGES
9.2.7. NIDEK CO LTD
9.2.7.1. COMPANY OVERVIEW
9.2.7.2. PRODUCT LIST
9.2.7.3. STRENGTHS & CHALLENGES
9.2.8. OPTOS PLC
9.2.8.1. COMPANY OVERVIEW
9.2.8.2. PRODUCT LIST
9.2.8.3. STRENGTHS & CHALLENGES
9.2.9. SANTEC CORPORATION
9.2.9.1. COMPANY OVERVIEW
9.2.9.2. PRODUCT LIST
9.2.9.3. STRENGTHS & CHALLENGES
9.2.10. TOPCON CORPORATION
9.2.10.1. COMPANY OVERVIEW
9.2.10.2. PRODUCT LIST
9.2.10.3. STRENGTHS & CHALLENGES


LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - RETINAL IMAGING DEVICES
TABLE 2: MARKET BY DEVICE, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 3: MARKET BY DEVICE, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 4: MARKET BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 5: MARKET BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 6: MARKET BY FUNDUS CAMERAS, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 7: MARKET BY FUNDUS CAMERAS, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 8: MARKET BY RETINAL ULTRASOUND IMAGING SYSTEMS, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 9: MARKET BY RETINAL ULTRASOUND IMAGING SYSTEMS, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 10: MARKET BY APPLICATION, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 11: MARKET BY APPLICATION, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 12: MARKET BY INDICATION, BY REGION, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 13: MARKET BY INDICATION, BY REGION, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 14: ASIA-PACIFIC MARKET, COUNTRY ANALYSIS, HISTORICAL YEARS, 2022-2024 (IN $ MILLION)
TABLE 15: ASIA-PACIFIC MARKET, COUNTRY ANALYSIS, FORECAST YEARS, 2026-2034 (IN $ MILLION)
TABLE 16: KEY PLAYERS OPERATING IN THE ASIA-PACIFIC MARKET
TABLE 17: LIST OF MERGERS & ACQUISITIONS
TABLE 18: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 19: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 20: LIST OF BUSINESS EXPANSIONS & DIVESTITURES


LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: SEGMENT GROWTH POTENTIAL, BY DEVICE, IN 2025
FIGURE 9: OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 10: SEGMENT GROWTH POTENTIAL, BY OPTICAL COHERENCE TOMOGRAPHY (OCT) DEVICES, IN 2025
FIGURE 11: SPECTRAL-DOMAIN OCT (SD-OCT) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 12: SWEPT-SOURCE OCT (SS-OCT) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 13: HANDHELD OCT MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 14: FLUORESCEIN ANGIOGRAPHY DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 15: FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 16: SEGMENT GROWTH POTENTIAL, BY FUNDUS CAMERAS, IN 2025
FIGURE 17: MYDRIATIC FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 18: NON-MYDRIATIC FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 19: HYBRID FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 20: ROP FUNDUS CAMERAS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 21: RETINAL ULTRASOUND IMAGING SYSTEMS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 22: SEGMENT GROWTH POTENTIAL, BY RETINAL ULTRASOUND IMAGING SYSTEMS, IN 2025
FIGURE 23: OPHTHALMIC A-SCAN ULTRASOUND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 24: OPHTHALMIC B-SCAN ULTRASOUND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 25: OPHTHALMIC ULTRASOUND BIOMICROSCOPES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 26: OPHTHALMIC PACHYMETERS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 27: ULTRA WIDEFIELD RETINAL IMAGING DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 28: WIDEFIELD RETINAL IMAGING DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 29: OTHER DEVICES MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 30: SEGMENT GROWTH POTENTIAL, BY APPLICATION, IN 2025
FIGURE 31: DISEASE DIAGNOSIS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 32: TREATMENT MONITORING MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 33: RESEARCH AND DEVELOPMENT MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 34: SEGMENT GROWTH POTENTIAL, BY INDICATION, IN 2025
FIGURE 38: DIABETIC RETINOPATHY MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 35: AGE-RELATED MACULAR DEGENERATION (AMD) MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 36: GLAUCOMA MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 37: RETINAL VEIN OCCLUSION MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 38: OTHER INDICATIONS MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 39: ASIA-PACIFIC RETINAL IMAGING DEVICES MARKET, COUNTRY OUTLOOK, 2025 & 2034 (IN %)
FIGURE 40: CHINA MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 41: INDIA MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 42: JAPAN MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 43: AUSTRALIA & NEW ZEALAND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 44: SOUTH KOREA MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 45: THAILAND MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 46: INDONESIA MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 47: VIETNAM MARKET SIZE, 2026-2034 (IN $ MILLION)
FIGURE 48: REST OF ASIA-PACIFIC MARKET SIZE, 2026-2034 (IN $ MILLION)